Abstract
In this article, we delineate a loosely selected cohort comprising patients with a history of early-onset breast cancer and/or a familial occurrence of cancer. The aim of this study was to gain insights into the presence of breast cancer-related gene variants in a population from a micro-region in southern Brazil, specifically the Metropolitan Region of Curitiba. This area exhibits a highly genetically mixed population, mirroring the general characteristics of the Brazilian people. Comprehensive next-generation sequencing (NGS) multigene panel testing was conducted, involving the evaluation of twelve patients. Two pathogenic variants and one candidate pathogenic variant were identified: BRCA2:c.8878C>T, p.Gln2960Ter; CHEK2:c.1100delAG>A, p.Thr367Metfs*15 and BRCA2:c.3482dupG>GA, p.Asp1161Glufs*3, a novel variant, previously unpublished, is reported.
Author Summary Breast cancer stands as one of the most prevalent cancers globally, affecting both genders, although it is much more common in women. Predominantly sporadic, around 5% to 10% of cases are attributed to hereditary factors, linked to specific gene mutations passed down through generations. Beyond BRCA1 and BRCA2, there is a growing understanding that breast cancer risk is influenced by a range of genes. In the pursuit of understanding and mitigating breast cancer risks, genetic testing plays a pivotal role. These tests draw upon extensive databases, repositories of genetic information, to decipher individual variations. However, the lack of population diversity representation in genetic research databases is a global concern, and Latin America is no exception, presenting challenges in ensuring inclusivity and relevance in genetic research and healthcare applications. Addressing this gap, our study focused on a population in the Metropolitan Region of Curitiba, Brazil, sought to uncover breast cancer-related genetic variants. Despite the modest cohort, the study identified two pathogenic and one novel candidate pathogenic variants. While a small contribution, this research endeavors to enrich the collective knowledge base surrounding breast cancer, illustrating the ongoing efforts to comprehend and address the complexities of this prevalent disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Genoprimer Diagnostico Molecular Research Ethics Board of Genoprimer Diagnostico Molecular gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
